BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 29210328)

  • 1. DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
    Ceppi F; Gagné V; Douyon L; Quintin CJ; Colombini A; Parasole R; Buldini B; Basso G; Conter V; Cazzaniga G; Krajinovic M
    Pharmacogenomics; 2018 Jan; 19(2):105-112. PubMed ID: 29210328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.
    Dulucq S; St-Onge G; Gagné V; Ansari M; Sinnett D; Labuda D; Moghrabi A; Krajinovic M
    Blood; 2008 Apr; 111(7):3692-700. PubMed ID: 18096764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.
    Al-Shakfa F; Dulucq S; Brukner I; Milacic I; Ansari M; Beaulieu P; Moghrabi A; Laverdière C; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Krajinovic M
    Clin Cancer Res; 2009 Nov; 15(22):6931-8. PubMed ID: 19861437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):589-595. PubMed ID: 28719513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
    Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
    Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
    Starý J; Gajdos P; Blazek B; Ptoszková H; Mihál V; Pospísilová D; Hrstková H; Dembická D; Kopecná L; Slavík Z; Hak J; Procházková D; Zahálka F; Cerná Z; Jabali Y; Timr P; Vávra V; Mydlil J; Hrusák O; Trka J
    Cas Lek Cesk; 2003; 142(7):404-9. PubMed ID: 14515443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
    Aricò M; Conter V; Valsecchi MG; Rizzari C; Boccalatte MF; Barisone E; Messina C; De Rossi G; Lo Nigro L; Pession A; Locatelli F; Micalizzi C; Basso G
    Haematologica; 2005 Sep; 90(9):1186-91. PubMed ID: 16154841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
    Stamati L; Avgeris M; Kosmidis H; Baka M; Anastasiou T; Piatopoulou D; Scorilas A; Gourgiotis D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2023-36. PubMed ID: 25982455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
    Badowska W
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia.
    Kodidela S; Pradhan SC; Dubashi B; Basu D
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1349-58. PubMed ID: 26335211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
    Biondi A; Rizzari C; Valsecchi MG; De Lorenzo P; Aricò M; Basso G; Locatelli F; Lo Nigro L; De Rossi G; Masera G
    Haematologica; 2006 Apr; 91(4):534-7. PubMed ID: 16537119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
    Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
    Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
    Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
    Holownia A; Trofimiuk E; Krawczuk-Rybak M; Jakubow P; Kaliszewski J; Muszynska-Roslan K; Braszko JJ
    Acta Haematol; 2004; 112(4):222-4. PubMed ID: 15564737
    [No Abstract]   [Full Text] [Related]  

  • 18. [Reults of treatment with protocols BFM 90 and BFM 95].
    Sakić M; Berbić-Fazlagić J
    Med Arh; 2006; 60(6):369-72. PubMed ID: 17297851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity].
    Karachunskiĭ AI; Miakova NV; Rumiantseva IuV; Timakov AM; Makhortykh TZh; Fechina LG; Shamardina AV; Dudkin SA; Lebedev VV; Varfolomeeva SR; Timofeeva VN; Herold R; Stakelberg A; Henze G; Rumiantsev AG
    Ter Arkh; 2007; 79(7):19-26. PubMed ID: 17802785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
    Glodkowska E; Bialas A; Jackowska T
    Med Wieku Rozwoj; 2007; 11(2 Pt 1):153-8. PubMed ID: 17625285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.